S. James

发表

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

B. Nilsson, G. Juliusson, M. Cragg, 2015, Cancer cell.

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

M. Cragg, M. Glennie, H. Chan, 2020, Journal for immunotherapy of cancer.

On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation

M. Cragg, A. Turner, D. Humphreys, 2021, Communications Biology.

Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant

A. Cunningham, M. Glennie, A. Tutt, 2010, Immunology.

Activation of GABA(A) receptors inhibits T cell proliferation

M. Cragg, S. Beers, S. James, 2021, PloS one.

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms

M. Cragg, A. Tutt, S. Beers, 2022, Cell reports.

CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses

M. Glennie, J. Teeling, R. French, 2008, European journal of immunology.

Death receptor 3 is essential for generating optimal protective CD41 T‐cell immunity against Salmonella

A. Cunningham, T. Ślebioda, S. James, 2011, European journal of immunology.

Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma

S. Beers, E. Williams, S. James, 2022, iScience.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcg Receptors

Jinny, M. Cragg, A. Vaughan, 2015 .

Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

M. Cragg, M. Glennie, Peter W. M. Johnson, 2013, Clinical Cancer Research.

Immune characterization of pre-clinical murine models of neuroblastoma

M. Cragg, S. Beers, M. Ashton-Key, 2020, Scientific Reports.

Proteomic Analysis of Mitotic RNA Polymerase II Reveals Novel Interactors and Association With Proteins Dysfunctional in Disease*

S. Q. Xie, Ana Pombo, M Madan Babu, 2011, Molecular & Cellular Proteomics.

Role of the pro-survival molecule Bfl-1 in melanoma.

M. Cragg, C. Harris, H. Chan, 2015, The international journal of biochemistry & cell biology.

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

M. Cragg, Rosanna C. G. Smith, M. Glennie, 2022, Journal of experimental & clinical cancer research : CR.

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

E. King, J. Parsons, G. Thomas, 2022, Cancer research.

Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies

M. Glennie, R. French, Peter W. M. Johnson, 2008, European journal of immunology.

Antibodies to Costimulatory Receptor 4‐1BB Enhance Anti‐tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

M. Cragg, E. Healy, A. Rogel, 2018, Immunity.

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

Jonathan J. West, M. Cragg, M. Glennie, 2017, Cancer cell.

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

M. Shlomchik, M. Cragg, M. Glennie, 2008, Blood.

activation I (rituximab-like) reagents in B-cell depletion regardless of complement Type II (tositumomab) anti-CD20 monoclonal antibody out performs type

M. Shlomchik, M. Cragg, M. Glennie, 2013 .

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity

M. Cragg, M. Crispin, M. Glennie, 2021, Communications biology.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors

M. Cragg, A. Vaughan, M. Glennie, 2015, The Journal of Immunology.

Reducing affinity as a strategy to boost immunomodulatory antibody agonism

J. Essex, M. Cragg, I. Tews, 2023, Nature.

This information is current as Receptors γ and Human Fc Monoclonal Antibodies Specific for Mouse Development and Characterization of Beers and

Jinny, M. Cragg, A. Vaughan, 2015 .

Role of the pro-survival molecule Bfl-1 in melanoma.

M. Cragg, C. Harris, H. Chan, 2015, The international journal of biochemistry & cell biology.

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

B. Nilsson, G. Juliusson, M. Cragg, 2015, Cancer cell.

Metronomic cyclophosphamide is more effective than a single dose in resistant tumours Cyclophosphamide depletes tumour infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma

S. Beers, E. Williams, S. James, 2022, iScience.

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

M. Shlomchik, M. Cragg, M. Glennie, 2008, Blood.

Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies

M. Glennie, R. French, Peter W. M. Johnson, 2008, European journal of immunology.

Proteomic Analysis of Mitotic RNA Polymerase II Reveals Novel Interactors and Association With Proteins Dysfunctional in Disease*

S. Q. Xie, M. Babu, M. Selbach, 2011, Molecular & Cellular Proteomics.

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

M. Cragg, M. Glennie, M. Rose-Zerilli, 2017, Cancer cell.

This information is current as Receptors γ and Human Fc Monoclonal Antibodies Specific for Mouse Development and Characterization of Beers and

Jinny, M. Cragg, A. Vaughan, 2015 .